Final Up to date on Might 16, 2022 by GlobeNewsWire
Presenting new information on ‘1104 in allergic illness on the American Thoracic Society Worldwide Convention in San Francisco on Might 17
Delivering an oral presentation on resetting the immune system to realize long-term illness remission on the Treg Summit in Boston on Might 19
NEW ORLEANS and LONDON, Might 16, 2022 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo Bio” or the “Firm”), an organization growing therapies that reset the immune system to realize superior long-term remission for sufferers with autoimmune and allergic illnesses, at present introduced that the Firm can be delivering shows at two upcoming medical conferences: the American Thoracic Society (ATS) Worldwide Convention and the Treg Summit.
“We’re happy to have a presence at these two vital medical conferences,” stated Jonathan Rigby, Group Chief Govt Officer of Revolo Biotherapeutics. “The brand new information introduced at ATS 2022 additional present the potential of ‘1104 for use within the medical setting each by means of subcutaneous (SC) or intravenous (IV) administration for the therapy of bronchial asthma and different allergic and inflammatory illnesses. ‘1104 is at the moment in two section 2 medical trials, one in allergic illness and one other in eosinophilic esophagitis (EoE), and enlargement of routes of administration reminiscent of SC enable for wider exploration into different allergic and inflammatory illnesses.”
“We’re additionally excited to take part at this yr’s Treg Summit and supply a evaluate of latest mechanisms directed at proliferating secure and lengthy lasting Tregs to reset the immune system and obtain superior long run illness remission. We can even supply an replace on each of our medical packages for our two drug candidates, ‘1104 and ‘1805. Each medicine enhance the variety of Tregs by way of a singular mechanism of motion to revive immune system stability, avoiding persistent irritation with out suppressing the immune system and probably offering a lot wanted therapies for sufferers affected by autoimmune and allergic illnesses,” Mr. Rigby concluded.
Particulars of the shows are as follows:
ATS 2022 Poster Presentation particulars – Might 13-18, San Francisco
Title: IRL201104, a Novel Immunomodulatory Peptide, Exhibits a Lengthy Lasting, Dose Response and Large Spectrum Impact By way of Completely different Routes of Administration in a Mannequin of Allergic Irritation
Poster Quantity: 504
Session: C21- Drilling down on inflammatory mechanisms in bronchial asthma by way of human cells and murine fashions
Poster Dialogue Time: Might 17, 2022, 9:30-11:30 am EDT (viewing: 9:30-10:00 am EDT; dialogue: 10:00-11:30 am EDT)
Room: 303-304 (South Constructing, Degree 3), Moscone Middle
Remedy with ‘1104 resulted in a long-lasting dose response by means of each IV and SC administration in a murine mannequin of allergic illness.’1104 led to a diminished inflammatory response at clinically related doses as seen by a discount of a full suite of cytokines and chemokines in each bronchoalveolar lavage and serum.
Treg Summit Oral Presentation particulars – Might 17-19, Boston
Format: Oral presentation
Title: A Revolutionary Method to Resetting the Immune System for Lengthy-Time period Illness Remission
Presenter: Dr Roly Foulkes, Chief Scientific Officer, Revolo
Presentation Time: Thursday, Might 19, 2022, 9:30-10:00 am EDT
Session: Eliciting Sturdy Responses to Overcome Relapse & Remission
Evaluation of a number of new mechanisms in improvement directed at proliferating secure and lengthy lasting Tregs to reset the immune system and obtain long run illness remissionDiscussion of ‘1104, a peptide in section 2 trials in eosinophilic esophagitis (EoE) and allergic diseaseReview of proof-of-concept trial of ‘1805 in section 2 trials in rheumatoid arthritis and non-infectious uveitis
‘1104 is a first-in-class peptide derived from a pure immune-regulatory protein, mTB Chaperonin 60.1 that’s concerned in resetting the immune system. Revolo Bio is advancing ‘1104 by means of two Part 2 trials: one in sufferers with eosinophilic esophagitis (EoE) and one in sufferers with allergen sensitivity, whereas exploring its potential for different allergic and inflammatory illnesses.
‘1805 is a modified analogue of the endogenous immune-regulatory binding immunoglobulin protein (BiP), a key participant in immune operate that resets the immune system for long-term illness remission. 1805’s tolerogenic properties have the potential to create efficient illness intervention throughout a number of indications and routes of administration.
About Revolo Biotherapeutics
Revolo Biotherapeutics is growing therapies that reset the immune system to realize superior long-term remission for sufferers with autoimmune and allergic illness, with out the immune system suppression seen with present therapies. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide respectively, reset the immune system to stop the persistent pro-inflammatory immune response that leads to autoimmune or allergic illness. ‘1104 is a peptide derived from a pure immune-regulatory protein and is being evaluated in a Part 2 medical trial for sufferers with eosinophilic esophagitis (EoE) and a Part 2 medical trial for allergic illness. ‘1805 is a modified analogue of a key protein in immune operate that’s making ready to enter a second Part 2 medical trial for moderate-to-severe rheumatoid arthritis and a Part 2 medical trial for non-infectious uveitis. The disease-agnostic mechanism of motion of Revolo Biotherapeutic’s belongings gives a possible platform for the event of therapies for a number of autoimmune and allergic illnesses.
For additional info, please go to www.revolobio.com.
Marylyn Rigby, VP Investor Relations & Advertising
Monica Rouco Molina, Ph.D.